Venture
Intarcia Therapeutics, Inc
Latest Form D 2020-01-14- CIK 1086688
- State CA
- Biotechnology
- 11 Form D offerings since 2009-12-02
- Total sold
- $1.2B
- across 11 offerings
- Rounds
- 11
- Form D offerings since 2009-12-02
- Latest round
- $198M
- 2019-03-12 · 021-334622
- Investors
- 45
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2019-03-12 · $198M
- 2009-12-02$9M021-56548
- 2010-05-14$14.5M021-142088
- 2010-09-07$45.8M021-147387
- 2012-08-22$7.3M021-183097
- 2012-11-29$699K021-187634
- 2012-11-29$7.9M021-187635
- 2012-11-29$156M021-187654
- 2014-04-07$200M021-215047
- 2016-09-15$525M021-270759
- 2017-01-13$3.6K021-278350
- 2019-03-12$198M021-334622
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($525M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-334622 | First filed2019-03-12 | Latest2020-01-14 | Sought$280M | Sold$198M | Investors45 | Exemptions506(b) |
| 021-278350 | First filed2017-01-13 | Latest2017-01-13 | Sought$3.6K | Sold$3.6K | Investors1 | Exemptions506(b) |
| 021-270759 | First filed2016-09-15 | Latest2017-08-04 | Sought$850M | Sold$525M | Investors90 | Exemptions506(b) |
| 021-215047 | First filed2014-04-07 | Latest2014-04-07 | Sought$200M | Sold$200M | Investors38 | Exemptions506(b) |
| 021-187654 | First filed2012-11-29 | Latest2012-11-29 | Sought$160M | Sold$156M | Investors23 | Exemptions506 |
| 021-187635 | First filed2012-11-29 | Latest2012-11-29 | Sought$7.9M | Sold$7.9M | Investors15 | Exemptions506 |
| 021-187634 | First filed2012-11-29 | Latest2012-11-29 | Sought$699K | Sold$699K | Investors4 | Exemptions506 |
| 021-183097 | First filed2012-08-22 | Latest2012-08-22 | Sought$7.3M | Sold$7.3M | Investors1 | Exemptions506 |
| 021-147387 | First filed2010-09-07 | Latest2012-08-30 | Sought$47.5M | Sold$45.8M | Investors35 | Exemptions506 |
| 021-142088 | First filed2010-05-14 | Latest2010-05-14 | Sought$16M | Sold$14.5M | Investors30 | Exemptions506 |
| 021-56548 | First filed2009-12-02 | Latest2010-01-15 | Sought$9M | Sold$9M | Investors33 | Exemptions506 |
Who backs Intarcia Therapeutics, Inc, inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2020-01-14
| Name | Relationship |
|---|---|
| Kurt Graves | RelationshipExecutive Officer, Director |
| Bryan Roberts | RelationshipDirector |
| Gino Santini | RelationshipDirector |
| Nancy Thornberry | RelationshipDirector |
| Patrick Conway | RelationshipDirector |
| Jim Rosenthal | RelationshipDirector |
| Jay Skyler | RelationshipDirector |
| Bob Kerrey | RelationshipDirector |
| David Spellman | RelationshipExecutive Officer |
| Raymond Keane | RelationshipExecutive Officer |
| Fred Fiedorek | RelationshipExecutive Officer |
| Thane Wettig | RelationshipExecutive Officer |
| Paul Feldman | RelationshipExecutive Officer |
| Anders Vinther | RelationshipExecutive Officer |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| Morgan Stanley & Co. LLC | CRD8209 | Broker-dealer— | Offerings2 |
| UBS Securities LLC | CRD7654 | Broker-dealer— | Offerings1 |
| Raptor International, LLC | CRD— | Broker-dealer— | Offerings1 |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b); Rule 506
- First filed
- 2009-12-02
- Latest filing
- 2020-01-14
Who backs Intarcia Therapeutics, Inc
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗